Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

Tumor-infiltrating lymphocytes (TILs) are an important histopathologic feature of colorectal
cancer that confer prognostic information. Previous clinical and epidemiologic studies have …

An impressive clinical success has been observed in treating a variety of cancers using
immunotherapy with programmed cell death‐1 (PD‐1) checkpoint blockade. However …

The anti-tumour immune response is critical to patient prognosis in colorectal cancer (CRC).
The aim of this study was to investigate infiltration of B lymphocytes into CRC tumours, and …

Molecular subtypes-based therapies offer new potential framework for desired and precise
outcome in clinical settings. Current treatment strategies in colorectal cancer are largely 'one …

Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune
responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated …

Background The immune response has important clinical value in colorectal cancer (CRC)
in both prognosis and response to immunotherapy. This study aims to explore tumour …

Existing preclinical models of human colorectal cancer (CRC) that rely on syngeneic
subcutaneous grafts are problematic, because of increasing evidence that the immune …

Paramount to the efficacy of immune checkpoint inhibitors is proper selection of patients with
adequate tumor immunogenicity and a robust but suppressed immune infiltrate. In colon …

The anti-tumor immune response has been shown to be of great prognostic importance in
colorectal cancer (CRC) and so has the tumors ability for immune evasion. Our aim of this …